GRI Bio announced the appointments of David Szekeres, Roelof Rongen, MSE, MBA, and Camilla Simpson, M.Sc. to the Company’s Board of Directors. Szekeres will serve as Chairman of the Board. As previously announced, GRI Bio will commence trading on The Nasdaq Capital Market under the ticker symbol "GRI", effective today, April 24, 2023, as a result of its recently completed its merger with Vallon Pharmaceuticals (VLON). David Szekeres has more than two decades of experience in the global life sciences industry as a finance and business development executive, deal maker, legal counsel and board member. Szekeres joined Heron Therapeutics (HRTX)as Chief Operating Officer and Head of Finance. Rongen currently serves as Chief Executive Officer of gene-therapy company, Adolore BioTherapeutics, Managing Partner of AsteRx Pharma Consulting and Founder/Chief Executive Officer of Innovative Molecules. Camilla Simpson serves as Chief Executive Officer of Zehna Therapeutics, an early-stage biotech and spin-out from the Cleveland Clinic.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on VLON:
- Vallon Pharmaceuticals Completes Merger with GRI Bio, Inc.
- Vallon Pharmaceuticals completes merger with GRI Bio
- Vallon Pharmaceuticals Announces Stockholder Approval of Merger with GRI Bio, Inc. and Reverse Stock Split
- Vallon Pharmaceuticals stockholders approve GRI Bio merger, reverse stock split
- Vallon Pharmaceuticals Adjourns Special Meeting of Stockholders Until April 20, 2023
